Optimal Donation of Kidney Transplants After Controlled Circulatory Death

Savoye et al. performed a retrospective analysis to assess early outcomes of kidney transplants in the French controlled donation after circulatory death (cDCD) program by comparing them to transplants from donation after brain death (DBD) donors in the French National cohort.  

The French cDCD protocol has three main characteristics: the use of normothermic regional perfusion (NRP) and hypothermic machine perfusion (HMP) while attempting to keep the cold ischemic time as short as possible. They included 499 cDCD and 6,185 DBD transplantations in the full cohort, and the matched cohort included 442 cDCD and 809 DBD transplants.

They found that:

  • The cDCD group had less DGF than the DBD group
  • Although slightly fewer graft failures in the cDCD group (5.0% vs 6.1%), it did not reach statistical significance
  • They found that the risk of DGF among DBD transplants was lower when hypothermic machine perfusion was used

Overall, the early outcomes for the French cDCD program were similar or better than comparable DBD transplants.

Read the full article here: https://doi.org/10.1111/ajt.16425

The Latest

Check out the most recent posts

Fox19—UC Health Performs First Cold Pump Liver Transplant

In this article from FOX19 NOW, meet the first liver transplant patient to receive a cold pump liver which was pumped on a LifePort® Liver Transporter during its clinical trial, PILOT™. PILOT (Perfusion to Improve Liver Outcomes in Transplantation) is a...

ABC12 News—Organ Transplant Goes Hi-tech

In this article, Intermountain Healthcare takes part in the PILOT™ clinical trial of the LifePort® Liver Transporter. PILOT (Perfusion to Improve Liver Outcomes in Transplantation) is a prospective randomized multi-center oxygenated hypothermic machine...

KSLTV—Doctors Testing New Liver Transplant Transport System

In this article, KSLTV of Salt Lake City reports on Intermountain Healthcare’s participation in the LifePort Liver Transporter clinical trial. “We’re keeping that liver working in a somewhat normal, physiologic state during the time that it’s out of the donor’s body...